Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Porvair reports half-year of growth

(Sharecast News) - Porvair reported a period of growth in the six months ended 31 May on Monday, with revenue rising 3% to £97.7m, or 5% higher on a constant currency basis. Adjusted operating profit edged up 1% to £12.6m, while operating profit increased 3% to £11.9m.

The London-listed firm said adjusted profit before tax rose 4% to £12m, and statutory profit before tax climbed 7% to £11.3m.

Adjusted basic earnings per share were up 3% at 20p, while basic earnings per share increased 5% to 19p.

Cash at the period end stood at £17.1m, up from £4.1m a year earlier, despite £2.3m of capital investment.

The interim dividend was raised slightly to 2.2p per share from 2.1p.

"The group has performed in line with expectations during the first six months of 2025," said chief executive Hooman Caman Javvi, reporting on his first set of results since taking the role.

"Trading has been mixed across our end markets, with strength in certain industrial businesses and laboratory instruments, offsetting softness in aerospace and foundry together with foreign exchange headwinds.

"Currently, the trading outlook for the second half of the year remains positive."

Javvi said that, since joining the group, he had visited its locations and met with its team across the business.

"I have been encouraged by our technical capabilities and the potential of the company, as it is facing end-markets with long-term growth potential."

Porvair said it was well positioned to benefit from long-term trends including tightening environmental regulation, demand for clean water, the growth of analytical science, the drive for carbon-efficient transport, the shift from plastic and steel to aluminium, and the push for higher manufacturing quality and efficiency.

At 1151 BST, shares in Porvair were down 3.96% at 741.4p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.